Biotech Late Stage Investors & VC Firms
652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.
Startup INVEST
ZurichPre-Seed–Late Stage
Teewinot Ventures
Pre-Seed–Late Stage
SymBiosis
BentonvilleSeed–Late Stage
4 people
Good Startup
BrusselsSeed–Late Stage
5 people
LDV Partners
Palo AltoPre-Seed–Late Stage
2 people
CIBC
TorontoPre-Seed–Late Stage$1.5M – $29.2M
1 person
Oceanpine Capital
BeijingSeed–Late Stage
5 people
Summitview Capital
ShanghaiSeed–Late Stage
5 people
Zhejiang Sino Wisdom Investment Co.,Ltd.
HangzhouSeries A–Late Stage
5 people
Longbow Capital LLP
NorwichSeries C–Late Stage$1.3M – $12.7M
2 people
Vincera Capital
TaipeiSeed–Late Stage$500K – $10M
2 people
ICICI Venture
MumbaiGrowth–Late Stage$500K – $2.5M
1 person
Japan Asia Investment
TokyoPre-Seed–Late Stage$1M – $10M
1 person
City Side Ventures LLC
BirminghamSeed–Late Stage$150K – $10M
1 person
Kenson Ventures, LLC
Menlo ParkSeed–Late Stage$500K – $3M
1 person
Advantech Capital
Camana BayGrowth–Late Stage
3 people
Company K Partners
SeoulSeed–Late Stage$2.2M – $44M
GVFL Ltd.
AhmedabadSeed–Late Stage$250K – $25M
Ameba Capital
ShanghaiSeed–Late Stage
3 people
ePlanet Capital
San JoseSeed–Late Stage
3 people
MSD Global Health Innovation Fund
RahwaySeries A–Late Stage$1M – $30M
SL Investment Ltd.
SeoulSeries A–Late Stage$500K – $2M
West Virginia Jobs Investment Trust
CharlestonSeed–Late Stage$100K – $1M
Yuanta Investment
SeoulSeed–Late Stage$1M – $15M
Related lists
Late Stage Investors & VC Firms (2974)Biotech Investors & VC Firms (2185)Biotech Seed Investors & VC Firms (1824)Late Stage Investors & VC Firms in North America (1695)Biotech Series A Investors & VC Firms (1668)Late Stage Investors & VC Firms in United States (1516)Biotech Investors & VC Firms in North America (1391)Biotech Investors & VC Firms in United States (1267)Late Stage Investors & VC Firms in Europe (965)Biotech Pre-Seed Investors & VC Firms (957)
Data sourced from public filings and firms' own websites — see our methodology.












